IBIO
iBio, Inc.
NASDAQ · Healthcare · Biotechnology · US
$1.25
+0.00%Next report
Analyst consensus
- Next report date
- Nov 11, 2026
- EPS estimate
- -$0.06
- Revenue estimate
- $20.0K
Latest reported
- Last report date
- Aug 28, 2026
- EPS actual
- -$0.04
- EPS estimate
- -$0.07
- Revenue actual
- —
- Revenue estimate
- $80.0K
Track record
Trailing twelve quarters
- EPS beats (12Q)
- 3
- EPS misses (12Q)
- 7
- EPS in line (12Q)
- 0
- Avg surprise (4Q)
- -3.6%
- Revenue beats (12Q)
- 3
Analyst ratings
Sell-side consensus
- Consensus
- Buy
- Price target
- $6.00
- PT range
- $5.00 – $7.00
- Analysts
- 2
2 Buy0 Hold0 Sell
Reported history
| Report date | EPS estimate | EPS actual | Surprise | Revenue actual |
|---|---|---|---|---|
| Aug 28, 2026 | -$0.07 | -$0.04 | Beat 38.97% | — |
| May 12, 2026 | -$0.06 | -$0.07 | Miss -16.67% | — |
| Nov 12, 2025 | -$0.07 | -$0.11 | Miss -57.14% | $100.0K |
| Sep 5, 2025 | -$0.39 | -$0.31 | Beat 20.51% | $200.0K |
| May 2, 2025 | -$0.39 | -$0.49 | Miss -25.64% | — |
| Sep 25, 2024 | -$0.47 | -$0.91 | Miss -93.62% | $175.0K |
| Feb 9, 2024 | — | -$2.42 | — | — |
| Nov 14, 2023 | — | -$4.20 | — | $50.0K |
| May 11, 2023 | -$3.42 | -$6.61 | Miss -93.36% | $200.0K |
| Feb 14, 2023 | -$147 | -$22 | Beat 85.30% | — |
| Nov 14, 2022 | -$1.85 | -$2.05 | Miss -10.81% | $56.0K |
| May 12, 2022 | -$1.25 | -$30 | Miss -2300.00% | $1.9M |
Reported results against consensus at the time of each report · Surprise is computed from the estimate on record · Data as of Nov 11, 2026